The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View GALT Detailed Price Forecast - CNN Money||View GALT Detailed Summary - Google Finance|
|View GALT Detailed Summary - Yahoo! Finance||View GALT Stock Research & Analysis - Zacks.com|
|View GALT Trends & Analysis - Trade-Ideas||View GALT Major Holders - Barrons|
|View GALT Call Transcripts - NASDAQ||View GALT Breaking News & Analysis - Seeking Alpha|
|View GALT Annual Report - CompanySpotlight.com||View GALT OTC Short Report - OTCShortReport.com|
|View GALT Fundamentals - TradeKing||View GALT SEC Filings - Bar Chart|
|View Historical Prices for GALT - The WSJ||View Performance/Total Return for GALT - Morningstar|
|View the Analyst Estimates for GALT - MarketWatch||View the Earnings History for GALT - CNBC|
|View the GALT Earnings - StockMarketWatch||View GALT Buy or Sell Recommendations - MacroAxis|
|View the GALT Bullish Patterns - American Bulls||View GALT Short Pain Metrics - ShortPainBot.com|
|View GALT Stock Mentions - StockTwits||View GALT Stock Mentions - PennyStockTweets|
|View GALT Stock Mentions - Twitter||View GALT Investment Forum News - Investor Hub|
|View GALT Stock Mentions - Yahoo! Message Board||View GALT Stock Mentions - Seeking Alpha|
|View Insider Transactions for GALT - SECform4.com||View Insider Transactions for GALT - Insider Cow|
|View GALT Major Holdings Summary - CNBC||View Insider Disclosure for GALT - OTC Markets|
|View Insider Transactions for GALT - Yahoo! Finance||View Institutional Holdings for GALT - NASDAQ|
|View GALT Stock Insight & Charts - FinViz.com||View GALT Investment Charts - StockCharts.com|
|View GALT Stock Overview & Charts - BarChart||View GALT User Generated Charts - Trading View|
Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks
Posted on Wednesday July 11, 2018
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).
Penny Stocks to Buy Using Technical Analysis
Posted on Friday June 29, 2018
July's technical analysis penny stock action list includes breakout, pullback and momentum plays, along with proposed stop losses.
Why Galectin Therapeutics Stock Bolted Higher Today
Posted on Wednesday June 27, 2018
Galectin's new patent for its lead drug candidate sent its shares higher today.
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Posted on Wednesday June 27, 2018
Galectin Therapeutics, Inc. (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631 titled "Method and Treatment of Pulmonary Fibrosis.” The patent's principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent is expected to provide broad protection for the use of GR-MD-02 for compositions, methods of using and methods of manufacturing compositions capable of treating pulmonary fibrosis. The patent coverage extends to 2032.